Subscribe to our Newsletters !!
Few developments in science and technology have be
In modern pharmaceutical and laboratory settings,
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceuticals Limited (Alembic) today an
2026 marks a new chapter for the pharmaceutical an
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Dr Reddy’s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization Gilead Sciences to fabricate and advertise remdesivir – a potential COVID-19 medication in 127 nations, including India.
According to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy’s Laboratories said in an announcement.
The organization will get innovation move from Gilead for assembling of the medication, it included.
Dr Reddy’s would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.
Remdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.
